Abstract P1-03-02: Preclinical efficacy of a novel and potent inhibitor of the MDM2-p53 axis AMG 232 in ER+ breast cancer model
PK De(Avera Health), B Leyland-Jones(Amgen (United States)), Amy Krie(Amgen (United States)), Justin D. Klein(Nationwide Children's Hospital), Charlotte R. Williams(Amgen (United States)), Jude Canon(Amgen (United States)), Kristin E Williams(Amgen (United States)), JH Carlson(Avera Health), N Dey(Avera Health), Tyler Jepperson(Avera Health)
Cited by 0
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|726
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
|Genome Medicine|2021|91
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
|JAMA|2024|75
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ
|JAMA Oncology|2024|16